ストックスクリーナーアプリを入手
20.02
2.05%
-0.42
アフターアワーズ：
20.20
0.18
+0.90%
前日終値:
$20.44
開ける：
$20.56
24時間の取引高:
1.25M
Relative Volume:
0.71
時価総額：
$1.88B
収益：
$203.45M
当期純損益:
$-351.45M
株価収益率:
-4.40
EPS:
-4.55
ネットキャッシュフロー:
$-369.41M
1週間 パフォーマンス:
-5.34%
1か月 パフォーマンス:
+39.51%
6か月 パフォーマンス:
+0.86%
1年 パフォーマンス:
+203.33%
1日の値動き範囲:
$19.96
$20.96
1週間の範囲:
$19.65
$22.07
52週間の値動き範囲:
$6.01
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
名前
Travere Therapeutics Inc
セクター
電話
888-969-7879
住所
3611 VALLEY CENTRE DR, SAN DIEGO
TVTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
20.02 | 1.88B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-21 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-09 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-03-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-12-05 | アップグレード | Citigroup | Neutral → Buy |
| 2023-11-20 | 開始されました | Citigroup | Neutral |
| 2023-09-22 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 再開されました | Evercore ISI | Outperform |
| 2023-07-21 | 開始されました | JP Morgan | Overweight |
| 2023-06-07 | 再開されました | Piper Sandler | Neutral |
| 2023-05-22 | 開始されました | TD Cowen | Outperform |
| 2023-05-05 | アップグレード | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-21 | アップグレード | Wedbush | Neutral → Outperform |
| 2022-12-14 | 開始されました | Stifel | Hold |
| 2022-12-05 | 開始されました | Wells Fargo | Overweight |
| 2022-09-21 | 開始されました | Bryan Garnier | Sell |
| 2022-07-14 | 再開されました | Canaccord Genuity | Buy |
| 2022-03-31 | 開始されました | Piper Sandler | Overweight |
| 2022-02-28 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-26 | ダウングレード | Wedbush | Outperform → Neutral |
すべてを表示
Travere Therapeutics Inc (TVTX) 最新ニュース
Travere, CSL gets standard EU approval for kidney disorder treatment - MSN
Travere Therapeutics to Participate at Upcoming Investor ConferencesMay 7, 2025 - BioSpace
Travere Therapeutics to Participate at Upcoming Investor Conferences | TVTX Stock News - GuruFocus
Homocystinuria Market Growth, Trends & Forecast 2025 | Leading - openPR.com
Travere therapeutics CEO sells $398k in stock By Investing.com - Investing.com Nigeria
Travere therapeutics CEO sells $398k in stock - Investing.com Australia
Travere therapeutics CFO sells shares worth $37,553 - Investing.com Australia
Travere therapeutics CFO sells shares worth $37,553 By Investing.com - Investing.com India
Travere Therapeutics Executives Sell Shares - TradingView
Travere Therapeutics anticipates FILSPARI approval for FSGS by September 2025 - MSN
(TVTX) Technical Data - news.stocktradersdaily.com
Analysts Have Made A Financial Statement On Travere Therapeutics, Inc.'s (NASDAQ:TVTX) First-Quarter Report - Yahoo
Travere Therapeutics (TVTX) Sees Promising Growth with FILSPARI - GuruFocus
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Travere Therapeutics Inc (TVTX): A Strategic SWOT Insig - GuruFocus
Travere Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Travere Therapeutics (TVTX) Rating and Price Target Update by We - GuruFocus
Travere Therapeutics (TVTX) Price Target Raised by Stifel | TVTX Stock News - GuruFocus
Travere Therapeutics Inc (TVTX) Q1 2025 Earnings Call Highlights: Robust Sales Growth Amidst ... - Yahoo
Travere Therapeutics Inc (TVTX) Q1 2025 Earnings Call Highlights: Robust Sales Growth Amidst Challenges - GuruFocus
Travere: Q1 Earnings Snapshot - Norwalk Hour
Travere Therapeutics Reports Strong Q1 2025 Financial Results - TipRanks
Travere Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Travere Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:TVTX) - Seeking Alpha
Earnings call transcript: Travere Therapeutics beats Q1 2025 EPS forecast By Investing.com - Investing.com South Africa
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Travere Therapeutics Reports First Quarter 2025 Financial Results - BioSpace
Earnings call transcript: Travere Therapeutics beats Q1 2025 EPS forecast - Investing.com
Travere Therapeutics (TVTX) Surpasses Revenue Expectations in Q1 - GuruFocus
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (TVTX) Travere Therapeutics Q1 Adjusted Loss Per Share $0.19 vs. FactSet Est Loss $0.36 - marketscreener.com
Travere Therapeutics, Inc. SEC 10-Q Report - TradingView
Travere Therapeutics (TVTX) Gains Standard EU Approval for Filsp - GuruFocus
European Commission Grants Standard Approval for Travere's Filsp - GuruFocus
Travere, CSL get standard EU nod for kidney drug (TVTX:NASDAQ) - Seeking Alpha
Travere, CSL Vifor Receive EU Marketing Approval for Filspari in IgA Nephropathy - marketscreener.com
Travere Therapeutics and CSL Vifor Announce Standard EU Approval - GuruFocus
Travere Therapeutics (TVTX) Gains Standard EU Approval for Filspari | TVTX Stock News - GuruFocus
How to interpret Travere Therapeutics Inc (TVTX)’s stock chart patterns - uspostnews.com
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy | TVTX Stock News - GuruFocus
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy - Business Wire
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy - The Manila Times
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy | CSLLY Stock News - GuruFocus
Cantor Fitzgerald maintains overweight on Travere Therapeutics stock By Investing.com - Investing.com Canada
Travere Therapeutics (TVTX) – Research Analysts’ Recent Ratings Updates - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Travere Therapeutics Inc (TVTX) 財務データ
収益
当期純利益
現金流量
EPS
Travere Therapeutics Inc (TVTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
May 05 '25 |
Sale |
21.05 |
18,924 |
398,350 |
419,173 |
| Heerma Peter | CHIEF COMMERCIAL OFFICER |
May 05 '25 |
Sale |
21.05 |
1,771 |
37,280 |
128,215 |
| ROTE WILLIAM E. | Chief Research Officer |
May 05 '25 |
Sale |
21.05 |
3,198 |
67,318 |
100,241 |
| REED ELIZABETH E | Chief Legal Officer and GC |
May 05 '25 |
Sale |
21.05 |
4,920 |
103,566 |
89,482 |
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):